BIO-RAD LABORATORIES, INC.

Bio-Rad Laboratories, Inc. (NASDAQ: BIO) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. The company operates through two primary business segments: Life Science, which generates approximately 40% of consolidated net sales, and Clinical Diagnostics, which accounts for approximately 60% of net sales.

The Life Science segment develops products used to separate, purify, characterize, and quantify biological materials including cells, proteins, and nucleic acids. These products serve research and biopharmaceutical laboratory environments, biopharmaceutical manufacturing, quality control processes, food safety testing, and science education applications. The company estimates the worldwide market for life science products it serves at approximately $19 billion.

The Clinical Diagnostics segment designs and manufactures diagnostic test systems, informatics solutions, test kits, and quality controls for clinical laboratories. The company supplies several thousand products supporting more than 300 clinical diagnostic tests within the in vitro diagnostics market, with an estimated worldwide market size of approximately $16 billion. Clinical diagnostics revenue is largely recurring, as laboratories standardize on specific testing platforms that generate ongoing sales of test kits and consumables.

Bio-Rad maintains direct operations in over 36 countries outside the United States, with approximately 60% of consolidated net sales generated internationally and Europe representing the largest international region. The company employs approximately 7,450 full-time employees worldwide, with roughly 46% located in the Americas, 36% in Europe, the Middle East and Africa, and 18% in Asia Pacific. The company operates in 37 different countries globally.

The company holds over 2,100 U.S. and international patents and numerous trademarks. Bio-Rad also maintains a significant investment in Sartorius AG, owning approximately 38% of outstanding ordinary shares and 28% of preference shares as of December 31, 2025, with a fair value of $5.67 billion. The company's website is www.bio-rad.com.